Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Inventor:
Van Wagenen; Bradford C.
Address:
Salt Lake City, UT
No. of patents:
29
Patents:












Patent Number Title Of Patent Date Issued
7202261 Calcilytic compounds April 10, 2007
The present invention features calcilytic compounds. "Calcilytic compounds" refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techn
7053104 Metabotropic glutamate receptor antagonists and their use for treating central nervous system di May 30, 2006
The present invention provides compounds, and pharmaceutical compositions containing those compounds, that are active at metabotropic glutamate receptors. The compounds are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.
6818660 Calcilytic compounds November 16, 2004
The present invention features calcilytic compounds. "Calcilytic compounds" refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and technique
6710088 Inorganic ion receptor-active compounds March 23, 2004
The present invention features compounds able to modulate one or more activities of an inorganic ion receptor and methods for treating diseases or disorders using such compounds. Preferred compounds can mimic or block the effect of extracellular calcium on a cell surface calcium receptor
6617358 Anticonvulsant and central nervous system-depressing bis(fluorophenyl)alkylamides and their uses September 9, 2003
Bis(Fluorophenyl)alkylamides have been chemically synthesized which possess beneficial pharmacological properties (e.g., anticonvulsant activity) useful for the treatment of neurological diseases or disorders, such as, for example, epilepsy, convulsions, and seizure disorders. The prefer
6521667 Calcilytic compounds February 18, 2003
The present invention features calcilytic compounds. "Calcilytic compounds" refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and technique
6432656 Calcilytic compounds August 13, 2002
The present invention features calcilytic compounds. "calcilytic compounds" refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and technique
6429207 Metabotropic glutamate receptor antagonists and their use for treating central nervous system di August 6, 2002
The present invention provides compounds, and pharmaceutical compositions containing those compounds, that are active at metabotropic glutamate receptors. The compounds are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.
6342532 Inorganic ion receptor active compounds January 29, 2002
The present invention features compounds able to modulate one or more activities of an inorganic ion receptor and methods for treating diseases or disorders using such compounds. Preferred compounds can mimic or block the effect of extracellular calcium on a cell surface calcium receptor
6313146 Calcium receptor-active molecules November 6, 2001
The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an
6306912 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of n October 23, 2001
Method for identifying a compound useful for the therapeutic treatment of a neurological disease or disorder such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease or Parkinson's Disease, or
6294531 Calcilytic compounds September 25, 2001
Novel arylalkylamino compounds exhibiting calcilytic properties are provided.
6211244 Calcium receptor-active compounds April 3, 2001
The present invention features compounds able to modulate one or more activities of an inorganic ion receptor and methods for treating diseases or disorders by modulating inorganic ion receptor activity. Preferably, the compound can mimic or block the effect of extracellular Ca.sup.2+ on
6071970 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of n June 6, 2000
Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral s
6051610 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of n April 18, 2000
Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral s
6031003 Calcium receptor-active molecules February 29, 2000
The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an
6022894 Method of using calcilytic compounds February 8, 2000
The present invention features calcilytic compounds. "Calcilytic compounds" refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and technique
6017965 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of n January 25, 2000
Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia o
6011068 Calcium receptor-active molecules January 4, 2000
The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an
6001884 Calcium receptor-active molecules December 14, 1999
The present invention features molecules which can modulate one or activities of an inorganic ion receptor. Preferably, the molecule can mimic or block the effect of extracellular Ca.sup.2+ on a calcium receptor. The preferred use of such molecules is to treat diseases or disorders
5981599 Inorganic ion receptor active compounds November 9, 1999
The present invention features compounds able to modulate one or more activities of an inorganic ion receptor and methods for treating diseases or disorders using such compounds. Preferred compounds can mimic or block the effect of extracellular calcium on a cell surface calcium receptor
5858684 Method of screening calcium receptor-active molecules January 12, 1999
The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an
5763494 Pharmaceutical compositions comprising isovaleramide June 9, 1998
Isovaleramide has been found to exhibit mild anxiolytic activity at low to moderate dosage levels and mildly sedative at somewhat higher dosage levels. In contrast to certain other materials thought to be anxiolytic or mildly sedative, isovaleramide is non-cytotoxic and does not paradoxi
5648541 Chiral reductions of imines leading to the syntheses of optically active amines July 15, 1997
A process for preparing an R enantiomer of a compound of the formula (I): ##STR1## wherein Ar is 3-methoxyphenyl, 3-chlorophenyl, or 1-naphthyl, and X is independently selected from the group consisting of H, F, Cl, Br, I, phenyl, CF.sub.3, CF.sub.2 H, CFH.sub.2, lower alkyl (e.g., M
5648540 Amine preparation July 15, 1997
A method of making (R)-N-[1-(3-methoxyphenyl)ethyl]-3-(2-chlorobenzene)propanamine which involves reducing the appropriate amidyl or iminyl precursor with an appropriate reducing agent. The appropriate amidyl or iminyl precursor is made from a synthesis involving the use of (R)-3
5633404 N-((R)-.alpha.-methyl-3-methoxybenzyl)-3-(2-chlorobenzene)propanamide May 27, 1997
A method of making ( R)- N-[1-(3-methoxyphenyl)ethyl]-3-(2-chlorobenzene)propanamine which involves reducing the appropriate amidyl or iminyl precursor with an appropriate reducing agent. The appropriate amidyl or iminyl precursor is made from a synthesis involving the use of ( R)-3-
5506268 Use of isovaleramide as a mild anxiolytic and sedative agent April 9, 1996
Isovaleramide has been found to exhibit mild anxiolytic activity at low to moderate dosage levels and mildly sedative at somewhat higher dosage levels. In contrast to certain other materials thought to be anxiolytic or mildly sedative, isovaleramide is non-cytotoxic and does not paradoxi
5504253 Amine preparation April 2, 1996
A method of making (R)-N-[1-(3-methoxyphenyl)ethyl]-3-(2-chlorobenzene)propanamine which involves reducing the appropriate amidyl or iminyl precursor with an appropriate reducing agent. The appropriate amidyl or iminyl precursor is made from a synthesis involving the use of (R)-3
5461032 Insecticidally effective peptides October 24, 1995
The invention provides insecticidally effective peptides isolatable from Diguetia spider venom, methods for preparing and using insecticides, and DNA encoding such insecticidally effective peptides.










 
 
  Recently Added Patents
Apparatus for touch screen avionic device
Display window with level of service graphical user interface
Memory elements with increased write margin and soft error upset immunity
Boundary acoustic wave device
Document layout method
Housekeeping cart
Release layer
  Randomly Featured Patents
Heteroarylamino and heteroarylsulfonamido substituted 3-benyzlaminomethyl piperidines and related compounds
Vertical mirror in a silicon photonic circuit
Integrated system for on-site cell acquisition, processing, and delivery
Method for treating benign prostatic hyperplasia with thermal therapy
Process for the synthesis of nucleoside analogs
Compact helical compressor for mobile use in a vehicle
Apparatus for treating wastewater from a chemical-mechanical polishing process used in chip fabrication
Treatment process
Exhaust gas purification device for an internal combustion engine
Coated fertilizer